Boundless Bio, a cancer therapeutics company, raised $100M in a US IPO, selling 6.25M shares at $16 each.

Boundless Bio, a cancer therapeutics company backed by Bayer AG, raised $100M in a US IPO, selling 6.25M shares at $16 each. The San Diego-based company, founded by ARCH Venture Partners, is a clinical-stage oncology company targeting extrachromosomal DNA in certain cancers. Boundless Bio's IPO is the first in over a month, ending a pause in biotech IPO activity, and the most for the sector in three years.

March 28, 2024
3 Articles